Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis

Sang Bong Ahn, Dae Won Jun, Sang Gyune Kim, Sae Hwan Lee, Hyun Phil Shin, Won Hyeok Choe, Ja Kyung Kim, Kyu Sik Jung, Do Young Kim, Jae Jun Shim, Soo Young Park, Yeon Seok Seo, Won Kim, Jae Il Chung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) on dialysis are difficult to treat and show higher dropout rates during treatment. The aim of this study was to analyze the treatment outcomes in patients with CHC and underlying end-stage renal disease on dialysis in Korea. Methods: A retrospective multi-center study of 35 patients with CHC and underlying ESRD on regular dialysis from 13 centers were analyzed. We investigated the tolerability and efficacy of pegylated interferon therapy with or without ribavirin on dialysis patients. Results: Twenty patients (57%) were genotype 1. Sixteen patients (46%) were treated with pegylated interferon monotherapy. Nineteen patients (54%) were treated with pegylated interferon and ribavirin. The overall sustained virological response (SVR) rate was 65.7% in all subjects. Thirteen patients (37%) dropped out before completion of treatment, and six patients (46.2%) showed SVR despite premature termination of treatment. Twenty patients (90.9%) achieved SVR among the 22 patients who completed the scheduled course. The most common side effects were anemia and neutropenia. The patients receiving ribavirin treatment showed a higher dropout rate (52.6% vs. 18.8%, p = 0.04) and higher SVR rate (68.4% vs. 62.5%, p = 0.07) compared to the pegylated interferon mono-treatment group. Conclusions: The difficulty in treating HCV patients with ESRD was attributed to higher dropout rate. However, despite the high dropout rate (37%), the SVR rate in genotype 1 was 65% and in genotypes 2 and 3 was 66%. Patients who completed the treatment showed a high SVR rate of 89.5%.

Original languageEnglish
Pages (from-to)292-296
Number of pages5
JournalEuropean Journal of Internal Medicine
Volume26
Issue number4
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Chronic Hepatitis C
Interferons
Dialysis
Safety
Therapeutics
Chronic Kidney Failure
Ribavirin
Genotype
Korea
Neutropenia
Anemia

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Ahn, Sang Bong ; Jun, Dae Won ; Kim, Sang Gyune ; Lee, Sae Hwan ; Shin, Hyun Phil ; Choe, Won Hyeok ; Kim, Ja Kyung ; Jung, Kyu Sik ; Kim, Do Young ; Shim, Jae Jun ; Park, Soo Young ; Seo, Yeon Seok ; Kim, Won ; Chung, Jae Il. / Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis. In: European Journal of Internal Medicine. 2015 ; Vol. 26, No. 4. pp. 292-296.
@article{8b464cf4ca9a4131868527266d76591b,
title = "Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis",
abstract = "Introduction: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) on dialysis are difficult to treat and show higher dropout rates during treatment. The aim of this study was to analyze the treatment outcomes in patients with CHC and underlying end-stage renal disease on dialysis in Korea. Methods: A retrospective multi-center study of 35 patients with CHC and underlying ESRD on regular dialysis from 13 centers were analyzed. We investigated the tolerability and efficacy of pegylated interferon therapy with or without ribavirin on dialysis patients. Results: Twenty patients (57{\%}) were genotype 1. Sixteen patients (46{\%}) were treated with pegylated interferon monotherapy. Nineteen patients (54{\%}) were treated with pegylated interferon and ribavirin. The overall sustained virological response (SVR) rate was 65.7{\%} in all subjects. Thirteen patients (37{\%}) dropped out before completion of treatment, and six patients (46.2{\%}) showed SVR despite premature termination of treatment. Twenty patients (90.9{\%}) achieved SVR among the 22 patients who completed the scheduled course. The most common side effects were anemia and neutropenia. The patients receiving ribavirin treatment showed a higher dropout rate (52.6{\%} vs. 18.8{\%}, p = 0.04) and higher SVR rate (68.4{\%} vs. 62.5{\%}, p = 0.07) compared to the pegylated interferon mono-treatment group. Conclusions: The difficulty in treating HCV patients with ESRD was attributed to higher dropout rate. However, despite the high dropout rate (37{\%}), the SVR rate in genotype 1 was 65{\%} and in genotypes 2 and 3 was 66{\%}. Patients who completed the treatment showed a high SVR rate of 89.5{\%}.",
author = "Ahn, {Sang Bong} and Jun, {Dae Won} and Kim, {Sang Gyune} and Lee, {Sae Hwan} and Shin, {Hyun Phil} and Choe, {Won Hyeok} and Kim, {Ja Kyung} and Jung, {Kyu Sik} and Kim, {Do Young} and Shim, {Jae Jun} and Park, {Soo Young} and Seo, {Yeon Seok} and Won Kim and Chung, {Jae Il}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.ejim.2015.03.011",
language = "English",
volume = "26",
pages = "292--296",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier",
number = "4",

}

Ahn, SB, Jun, DW, Kim, SG, Lee, SH, Shin, HP, Choe, WH, Kim, JK, Jung, KS, Kim, DY, Shim, JJ, Park, SY, Seo, YS, Kim, W & Chung, JI 2015, 'Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis', European Journal of Internal Medicine, vol. 26, no. 4, pp. 292-296. https://doi.org/10.1016/j.ejim.2015.03.011

Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis. / Ahn, Sang Bong; Jun, Dae Won; Kim, Sang Gyune; Lee, Sae Hwan; Shin, Hyun Phil; Choe, Won Hyeok; Kim, Ja Kyung; Jung, Kyu Sik; Kim, Do Young; Shim, Jae Jun; Park, Soo Young; Seo, Yeon Seok; Kim, Won; Chung, Jae Il.

In: European Journal of Internal Medicine, Vol. 26, No. 4, 01.05.2015, p. 292-296.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis

AU - Ahn, Sang Bong

AU - Jun, Dae Won

AU - Kim, Sang Gyune

AU - Lee, Sae Hwan

AU - Shin, Hyun Phil

AU - Choe, Won Hyeok

AU - Kim, Ja Kyung

AU - Jung, Kyu Sik

AU - Kim, Do Young

AU - Shim, Jae Jun

AU - Park, Soo Young

AU - Seo, Yeon Seok

AU - Kim, Won

AU - Chung, Jae Il

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) on dialysis are difficult to treat and show higher dropout rates during treatment. The aim of this study was to analyze the treatment outcomes in patients with CHC and underlying end-stage renal disease on dialysis in Korea. Methods: A retrospective multi-center study of 35 patients with CHC and underlying ESRD on regular dialysis from 13 centers were analyzed. We investigated the tolerability and efficacy of pegylated interferon therapy with or without ribavirin on dialysis patients. Results: Twenty patients (57%) were genotype 1. Sixteen patients (46%) were treated with pegylated interferon monotherapy. Nineteen patients (54%) were treated with pegylated interferon and ribavirin. The overall sustained virological response (SVR) rate was 65.7% in all subjects. Thirteen patients (37%) dropped out before completion of treatment, and six patients (46.2%) showed SVR despite premature termination of treatment. Twenty patients (90.9%) achieved SVR among the 22 patients who completed the scheduled course. The most common side effects were anemia and neutropenia. The patients receiving ribavirin treatment showed a higher dropout rate (52.6% vs. 18.8%, p = 0.04) and higher SVR rate (68.4% vs. 62.5%, p = 0.07) compared to the pegylated interferon mono-treatment group. Conclusions: The difficulty in treating HCV patients with ESRD was attributed to higher dropout rate. However, despite the high dropout rate (37%), the SVR rate in genotype 1 was 65% and in genotypes 2 and 3 was 66%. Patients who completed the treatment showed a high SVR rate of 89.5%.

AB - Introduction: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) on dialysis are difficult to treat and show higher dropout rates during treatment. The aim of this study was to analyze the treatment outcomes in patients with CHC and underlying end-stage renal disease on dialysis in Korea. Methods: A retrospective multi-center study of 35 patients with CHC and underlying ESRD on regular dialysis from 13 centers were analyzed. We investigated the tolerability and efficacy of pegylated interferon therapy with or without ribavirin on dialysis patients. Results: Twenty patients (57%) were genotype 1. Sixteen patients (46%) were treated with pegylated interferon monotherapy. Nineteen patients (54%) were treated with pegylated interferon and ribavirin. The overall sustained virological response (SVR) rate was 65.7% in all subjects. Thirteen patients (37%) dropped out before completion of treatment, and six patients (46.2%) showed SVR despite premature termination of treatment. Twenty patients (90.9%) achieved SVR among the 22 patients who completed the scheduled course. The most common side effects were anemia and neutropenia. The patients receiving ribavirin treatment showed a higher dropout rate (52.6% vs. 18.8%, p = 0.04) and higher SVR rate (68.4% vs. 62.5%, p = 0.07) compared to the pegylated interferon mono-treatment group. Conclusions: The difficulty in treating HCV patients with ESRD was attributed to higher dropout rate. However, despite the high dropout rate (37%), the SVR rate in genotype 1 was 65% and in genotypes 2 and 3 was 66%. Patients who completed the treatment showed a high SVR rate of 89.5%.

UR - http://www.scopus.com/inward/record.url?scp=84928826993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928826993&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2015.03.011

DO - 10.1016/j.ejim.2015.03.011

M3 - Article

C2 - 25877760

AN - SCOPUS:84928826993

VL - 26

SP - 292

EP - 296

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 4

ER -